Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (GB:0SGC)
LSE:0SGC
Holding GB:0SGC?
Track your performance easily
0SGC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.70 - $3.92
Previous Close$3.8
Volume1.80K
Average Volume (3M)2.77K
Market Cap
$723.04M
Enterprise Value$582.65M
Total Cash (Recent Filing)$141.99M
Total Debt (Recent Filing)$1.60M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 06, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding188,782,029
10 Day Avg. Volume2,125
30 Day Avg. Volume2,767
Standard Deviation0.17
R-Squared0.06
Alpha0.00486
Financial Highlights & Ratios
Price to Book (P/B)5.90
Price to Sales (P/S)71.87
Price to Cash Flow (P/CF)-12.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue57.91
Enterprise Value/Gross Profit32.12
Enterprise Value/Ebitda-7.71
Forecast
1Y Price Target
$4.50Price Target Upside18.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arbutus Biopharma News
PremiumCompany Announcements
Arbutus Biopharma and Moderna Agree to Delay Patent Trial
PremiumCompany Announcements
Arbutus Biopharma’s Promising Hepatitis B Drug Trials
PremiumPre-Earnings
Is ABUS a Buy, Before Earnings?
PremiumCompany Announcements
Arbutus Biopharma Sets Q2 2024 Financial Results Date
PremiumCompany Announcements
Arbutus Reports Promising Hepatitis B Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsArbutus reported further follow-up data from the Phase 2a IM-PROVE I study, showing six patients in the A1 and A2 cohorts reached undetectable levels of HBsAg as of the end of the 24-week period of nuc-only treatment and have achieved seroconversion.
Combination TherapyThe combination therapy with imdusiran and VTP-300 shows sustained reductions in HBsAg levels in patients with chronic HBV.
Financial PositionThe company believes its current cash position is sufficient to fund operations into the fourth quarter of 2026.
Bears Say
Business OperationsThe company announced that it is ceasing all HBV drug discovery efforts, which will result in a workforce reduction of 40%.
Financial PerformanceThe company will take a one-time restructuring charge of ~$3-4M.
Legal IssuesThe case against Moderna remains on track for an April 21, 2025 trial date, with expert depositions and reports the next steps.
---
0SGC FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest share price was $1.70 and its highest was $3.92 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Currently, no data Available
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is Nov 06, 2024 which is in 66 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on Aug 01, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.096 by -$0.014.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -$0.09.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 188,782,030 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.096. Following the earnings report the stock price went down -2.168%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Woodline Partners LP. It holds Arbutus Biopharma Corporation’s shares valued at 3M.
---
Arbutus Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (18.58% Upside)
$4.50 (18.58% Upside)
Blogger Sentiment
Bullish
GB:0SGC Sentiment 100%
Sector Average 68%
Sector Average 68%
Insider Transactions
Sold Shares
Worth $32.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.58%
12-Months-Change
Fundamentals
Return on Equity
-59.96%
Trailing 12-Months
Asset Growth
-9.49%
Trailing 12-Months
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
0SGC Earnings Call
Q4 2024
0:00 / 0:00
---
0SGC Stock 12 Month Forecast
Average Price Target
$4.50
▲(18.58% Upside)
Technical Analysis
Best Analysts Covering 0SGC
1 Year
1 Year Success Rate
14/37 ratings generated profit
1 Year Average Return
-11.35%
reiterated a buy rating last month
Copying Keay Nakae's trades and holding each position for 1 Year would result in 37.84% of your transactions generating a profit, with an average return of -11.35% per trade.
---